Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 1

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT02065882Phase 3Completed

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Role: collaborator

NCT04763759Phase 1Completed

Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections

Role: collaborator

NCT03503630Phase 2Unknown

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Role: collaborator

NCT03480230Phase 2Unknown

Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Role: collaborator

All 4 trials loaded